Skip to main content

Silence Therapeutics plc

corporate_fare Company Profile

Silence Therapeutics plc

SLN·NASDAQ·Life Sciences·CIK 0001479615

We are a biotechnology company focused on discovering and developing new molecules that use short interfering ribonucleic acid (siRNA) to stop specific target genes from expressing. These genes are believed to contribute to diseases with significant unmet medical needs. Our siRNA molecules are designed to utilize the body's natural RNA interference (RNAi) mechanism by specifically attaching to and breaking down messenger RNA (mRNA) molecules that code for particular disease-associated proteins within a cell. By degrading the mRNA that codes for a disease-associated protein, the production of that protein is reduced, and its activity level is lowered. This reduction in disease-associated protein production and activity is known as "gene silencing" in RNAi therapeutics. Our proprietary mRNAi GOLD™ (GalNAc Oligonucleotide Discovery) platform creates siRNA product candidates designed to precisely target and 'silence' specific disease-associated genes in the liver. Through this platform, we have developed siRNA product candidates for rare and common diseases where current treatments are limited or insufficient. For rare diseases, Divesiran (SLN124) is our potential first-in-class siRNA in Phase 2 development for polycythemia vera (PV). PV is a rare myeloproliferative neoplasm characterized by an overproduction of red blood cells (RBCs). A key indicator of PV is elevated hematocrit (HCT), which is an index of RBC mass. HCT levels above 45% increase the risk of thrombotic and cardiovascular events. Divesiran works by "silencing" the TMPRSS6 gene, which removes the natural inhibition on hepcidin, the body's main iron regulator. When TMPRSS6 is reduced in individuals with PV, hepcidin levels increase, decreasing iron availability to the bone marrow. With less iron available, the excessive production of RBCs seen in PV is reduced. This helps maintain HCT levels within a safer range and can lessen or eliminate the need for phlebotomies. Additionally, siRNA therapies offer a highly potent and lasting effect, allowing for less frequent and more convenient dosing.

Silence Therapeutics plc (NASDAQ:SLN) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 25 items for SLN at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-19, rated 10/10. Across its 20 most recent items scored 7 or higher, the top rating is 10/10, with 15 rated 8 or above. Recent SEC coverage for SLN spans 8-K, SCHEDULE 13D/A, 4, 424B5.

Recent high-impact activity:

  • Merck KGaA to Acquire Silence Therapeutics for $20.00/ADS in $1.3B All-Cash Deal
  • Merck KGaA to Acquire Silence Therapeutics in Takeover Deal
  • Silence Therapeutics Closes $201M Upsized Offering After Full Underwriter Option Exercise
  • Controlling Shareholder Richard Griffiths Sells $87.7M in ADSs, Stake Falls to 7.97%
  • 10% Owner Richard Griffiths Sells 5.48M ADSs for ~$88M

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$559K
Net Income
-$88.61M
Diluted EPS
-$0.63
Op. Cash Flow
-$62.27M
Free Cash Flow
-$62.33M
Gross Profit
$344K
Operating Income
-$91.08M
Cash & Equivalents
$11.28M
Debt / Equity
0.00×
Net Margin
-158.52×
Shares Outstanding
141.7M sh
Source: 10-K · filed 2026-03-05 · accession 0001193125-26-092591

Short Interest & Short Volume

1.00 days to cover

FINRA reported short interest of 2,418,248 shares in SLN as of the October 30, 2026 settlement, a 17.4% decrease from the prior period — about 1.0 days to cover at its recent average daily volume. On November 20, 2026, 45.2% of SLN volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)2,418,248 shares as of October 30, 2026
Change vs prior period▼ 17.4%
Days to cover1.00 at avg daily volume of 9,216,885
Daily short volume (FINRA facilities)45.2% of 172,974 shares on November 20, 2026
5-day average short volume20.1%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Moderate risk

Filing-implied dilution signals for SLN, detected from its recent SEC filings · based on capital-structure filings through 2026-08-12.

2 recent capital raisesATM program1 shelf registration

Offering Priced at $13.50/ADS · Net Proceeds of $164 Million

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with S →
$19.85 +0.20% today
52-week range · as of 2026-10-19 $4.19 – $19.85
Market cap
$1.23B
Volume
399.1K (0.1× avg)
3-mo avg 4.2M
Live data · 2026-11-21 16:54 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed SLN - Latest Insights

SLN
Oct 19, 2026, 8:05 AM EDT
Filing Type: 8-K
Importance Score:
10
Price at Filing: $9.10
Real-time Price: $19.85 info
Change: +$10.75 (+118%) info
Market Cap: $1.232B info
SLN
Oct 19, 2026, 8:00 AM EDT
Source: Dow Jones Newswires
Importance Score:
10
Price at Filing: $9.10
Real-time Price: $19.85 info
Change: +$10.75 (+118%) info
Market Cap: $1.232B info
SLN
Aug 14, 2026, 4:55 PM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $13.72
Real-time Price: $19.85 info
Change: +$6.13 (+45%) info
Market Cap: $1.232B info
SLN
Aug 13, 2026, 9:55 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
8
Price at Filing: $14.00
Real-time Price: $19.85 info
Change: +$5.85 (+42%) info
Market Cap: $1.232B info
SLN
Aug 13, 2026, 10:07 AM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $14.15
Real-time Price: $19.85 info
Change: +$5.70 (+40%) info
Market Cap: $1.232B info
SLN
Aug 12, 2026, 5:23 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $13.95
Real-time Price: $19.85 info
Change: +$5.90 (+42%) info
Market Cap: $1.232B info
SLN
Aug 12, 2026, 5:21 PM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $13.95
Real-time Price: $19.85 info
Change: +$5.90 (+42%) info
Market Cap: $1.232B info
SLN
Aug 11, 2026, 11:20 PM EDT
Source: BusinessWire
Importance Score:
9
Price at Filing: $14.88
Real-time Price: $19.85 info
Change: +$4.97 (+33%) info
Market Cap: $1.232B info
SLN
Aug 11, 2026, 9:59 PM EDT
Filing Type: S-3MEF
Importance Score:
8
Price at Filing: $14.88
Real-time Price: $19.85 info
Change: +$4.97 (+33%) info
Market Cap: $1.232B info
SLN
Aug 10, 2026, 5:03 PM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $16.19
Real-time Price: $19.85 info
Change: +$3.66 (+23%) info
Market Cap: $1.232B info
SLN
Aug 10, 2026, 4:01 PM EDT
Source: BusinessWire
Importance Score:
8
Price at Filing: $15.43
Real-time Price: $19.85 info
Change: +$4.42 (+29%) info
Market Cap: $1.232B info
SLN
Aug 10, 2026, 7:57 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $16.05
Real-time Price: $19.85 info
Change: +$3.80 (+24%) info
Market Cap: $1.232B info
SLN
Aug 10, 2026, 7:30 AM EDT
Source: BusinessWire
Importance Score:
9
Price at Filing: $12.20
Real-time Price: $19.85 info
Change: +$7.65 (+63%) info
Market Cap: $1.232B info
SLN
Aug 10, 2026, 7:26 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $12.20
Real-time Price: $19.85 info
Change: +$7.65 (+63%) info
Market Cap: $1.232B info
SLN
Jul 08, 2026, 7:00 AM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
8
Price at Filing: $10.00
Real-time Price: $19.85 info
Change: +$9.85 (+99%) info
Market Cap: $1.232B info
SLN
Jul 07, 2026, 9:09 AM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $10.65
Real-time Price: $19.85 info
Change: +$9.20 (+86%) info
Market Cap: $1.232B info
SLN
Jun 23, 2026, 4:35 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $7.27
Real-time Price: $19.85 info
Change: +$12.58 (+173%) info
Market Cap: $1.232B info
SLN
Jun 11, 2026, 7:35 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $6.68
Real-time Price: $19.85 info
Change: +$13.18 (+197%) info
Market Cap: $1.232B info
SLN
May 27, 2026, 4:53 PM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $6.80
Real-time Price: $19.85 info
Change: +$13.05 (+192%) info
Market Cap: $1.232B info
SLN
May 18, 2026, 5:00 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $6.23
Real-time Price: $19.85 info
Change: +$13.62 (+219%) info
Market Cap: $1.232B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets